Weight Loss in Adults Using Semaglutide (Real-world Study)
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
35,000estimated
Sites
2
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-12 | estimated | When the study began enrolling |
| Primary completion | 2026-06-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-01 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Overweight
- Obesity
Intervention
- Drug: Semaglutide
Primary outcomes
what the primary-completion date above is the date OFChange in body weight
measured From index date (day 0) to week 68 (day 476)
Change in body weight
measured From index date (day 0) to week 68 (day 476)
Proportion of individuals achieving a clinically meaningful weight loss
measured From index date (day 0) to week 68 (day 476)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed